Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 4/20 | 0.47 |
| ▸ | RXRA | P19793 | 3/20 | 0.47 |
| ▸ | ACLY | P53396 | 7/20 | 0.37 |
| ▸ | RARA | P10276 | 3/20 | 0.34 |
| ▸ | RARB | P10826 | 3/20 | 0.34 |
| ▸ | RARG | P13631 | 3/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31191610 | 0.93 | RXRA (0.38) | RXRBRXRAACLYCA1CA2 | |
| SCHEMBL3664131 | 0.93 | RXRB (0.55) | RXRBRXRARARARARBRARG | |
| SCHEMBL30855392 | 0.93 | RXRB (0.55) | RXRBRXRARARARARBRARG | |
| SCHEMBL362701 | 0.93 | RXRB (0.41) | RXRBRXRARARARARBRARG | |
| SCHEMBL29397265 | 0.93 | RXRB (0.41) | RXRBRXRARARARARBRARG | |
| SCHEMBL2014009 | 0.93 | RXRB (0.41) | RXRBRXRARARARARBRARG | |
| SCHEMBL12274098 | 0.93 | RXRB (0.41) | RXRBRXRARARARARBRARG | |
| SCHEMBL29385555 | 0.93 | RXRB (0.41) | RXRBRXRARARARARBRARG | |
| Hydrochloric Acid SCHEMBL1566413 | 0.92 | RXRB (0.40) | RXRBRXRARARARARBRARG | |
| SCHEMBL30821160 | 0.92 | GPR52 (0.40) | RXRBRXRACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059897-A | Synthesis method of fluorine Lei Lana derivative | 济南久隆医药科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122059897-A | Synthesis method of fluorine Lei Lana derivative | 济南久隆医药科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20250380697-A1 | ISOXAZOLINE DERIVATIVE COMPOUND AND INSECTICIDAL COMPOSITION COMPRISING SAME | KYUNG NONG CORPORATION (KR) | 2025-12-18 | — | — | US | disclosed |
| CN-118878475-B | Isoxazoline-containing amide compound and preparation method and application thereof | 江西众和化工有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118930531-A | Isoxazoline derivative and preparation method and application thereof | 山东省联合农药工业有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118878475-A | Isoxazoline-containing amide compound and preparation method and application thereof | 江西众和化工有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-114591259-B | Preparation of isoxazole compounds | 江苏慧聚药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-11357231-B2 | Insecticidal compounds based on isoxazoline derivatives | SYNGENTA CROP PROTECTION LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-11357231-B2 | Insecticidal compounds based on isoxazoline derivatives | SYNGENTA CROP PROTECTION LLC (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114591259-A | Preparation of isoxazole compounds | 江苏慧聚药业股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-8735362-B2 | Insecticidal compounds based on isoxazoline derivatives | SYNGENTA CROP PROTECTION, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735362-B2 | Insecticidal compounds based on isoxazoline derivatives | SYNGENTA CROP PROTECTION, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2013050302-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050302-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| EP-2507230-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | Syngenta Participations AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20120238517-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238517-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238517-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2011067272-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067272-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238517-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES | CHRM1, ACHE, CHRM2 | RXRB 4311/4885RXRA 4034/4885ACLY 526/4885 |
| US-11357231-B2 | Insecticidal compounds based on isoxazoline derivatives | CYP4X1, NPY4R, CASP3 | RXRB 994/4885RXRA 889/4885ACLY 979/4885 |
| US-20250380697-A1 | ISOXAZOLINE DERIVATIVE COMPOUND AND INSECTICIDAL COMPOSITION COMPRISING SAME | VIP, CASP7, CYP4X1 | RXRB 849/4885RXRA 1013/4885ACLY 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.